4 November 2020
Novartis approved a 600K euro grant proposal from Frans Cremers, Susanne Roosing and Alexander Hoischen. To identify individuals with congenital blindness or retinitis pigmentosa due to RPE65 mutations, 4.000 probands from all over the world will be sequenced for mutations in ~100 genes based on the smMIP-target-enrichment technology and the NovaSeq6000 sequencing platform.